Table 1.
Influence of IDO1 and AhR modulation on model disease endpoints
| Disease model | IDO modulation | Impact on disease outcomes | Reference(s) |
|---|---|---|---|
|
| |||
| Arthritis | Inhibition (1MT) | Exacerbates disease | 162, 163 |
|
| |||
| Asthma | Activation (TLR9 ligand) | Ameliorates disease | 164 |
|
| |||
| EAE | Inhibition (1MT) | Exacerbates disease | 165 |
|
| |||
| Colitis | Inhibition (1MT) | Exacerbates disease | 92 |
| IDO1 knockout | Exacerbates disease | 166 | |
|
| |||
| EAE | Activation (TCDD) | Ameliorates disease | 100 |
| Activation (FICZ) | Exacerbates disease | 100, 167 | |
| Activation (ITE) | Ameliorates disease | 168 | |
|
| |||
| Arthritis | T cell–specific deletion | Ameliorates disease | 98 |
|
| |||
| Psoriasis | Activation (FICZ) | Ameliorates disease | 101 |
| Whole-body deletion | Exacerbates disease | 101 | |
| Cell-specific deletion(s) | Exacerbates disease | 101 | |
|
| |||
| Allergy-induced airway inflammation | Activation (TCDD) | Ameliorates disease | 169 |
| Activation (curcumin) | Ameliorates disease | 170 | |
|
| |||
| COPD | Whole-body deletion | Exacerbates disease | 171 |
|
| |||
| Pancreatitis | Activation (biliverdin) | Ameliorates disease | 172 |
|
| |||
| Colitis | Activation (FICZ) | Ameliorates disease | 103, 173 |
| Epithelial-specific deletion | Exacerbates disease | 174 | |
| T cell–specific deletion | Ameliorates disease | 174 | |